Advertisement
Advertisement
FOLD
Amicus Therapeutics, Inc
14.34
USDSponsored
+0.01
+0.03%
Mar 06, 10:07 UTC -5
Closed
After-Market
14.38
+0.05
+0.32%
FOLD Earnings Reports
Positive Surprise Ratio
FOLD beat 14 of 41 last estimates.
34%
Next Report
Date of Next Report
Apr 29, 2026
Estimate for Q1 26 (Revenue/ EPS)
$165.25M
/$0.03
Implied change from Q4 25 (Revenue/ EPS)
-10.78%
/--
Implied change from Q1 25 (Revenue/ EPS)
+31.94%
/-142.86%
Amicus Therapeutics, Inc earnings per share and revenue
On Feb 20, 2026, FOLD reported earnings of 0.00 USD per share (EPS) for Q4 25, missing the estimate of 0.08 USD, resulting in a -94.35% surprise. Revenue reached 185.21 million, compared to an expected 184.30 million, with a 0.49% difference. The market reacted with a -0.07% price change (close before vs. close after earnings).
Looking ahead to Q1 26, 9 analysts forecast an EPS of 0.03 USD, with revenue projected to reach 165.25 million USD, implying an -- of --% EPS, and decrease of -10.78% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Liquidia Corporation Common Stock
Report Date
Mar 05, 2026 For Q4 25
Estimate
$0.18
Actual
$0.15
Surprise
-18.48%
Kura Oncology, Inc.
Report Date
Mar 05, 2026 For Q4 25
Estimate
-$0.62
Actual
-$0.92
Surprise
-47.84%
CorMedix Inc.
Report Date
Mar 05, 2026 For Q4 25
Estimate
$0.83
Actual
$0.61
Surprise
-26.73%
REGENXBIO Inc.
Report Date
Mar 05, 2026 For Q4 25
Estimate
-$0.97
Actual
-$1.30
Surprise
-33.31%
Lexicon Pharmaceuticals, Inc.
Report Date
Mar 05, 2026 For Q4 25
Estimate
-$0.07
Actual
-$0.04
Surprise
+43.18%
Contineum Therapeutics, Inc. Class A Common Stock
Report Date
Mar 05, 2026 For Q4 25
Estimate
-$0.41
Actual
-$0.49
Surprise
-18.41%
Niagen Bioscience, Inc. Common Stock
Report Date
Mar 04, 2026 For Q4 25
Estimate
$0.02
Actual
$0.03
Surprise
+33.93%
Lineage Cell Therapeutics, Inc.
Report Date
Mar 05, 2026 For Q4 25
Estimate
-$0.05
Actual
$0.00
Surprise
+100.00%
Atea Pharmaceuticals, Inc. Common Stock
Report Date
Mar 05, 2026 For Q4 25
Estimate
-$0.54
Actual
-$0.56
Surprise
-5.44%
Aligos Therapeutics, Inc. Common Stock
Report Date
Mar 05, 2026 For Q4 25
Estimate
-$1.88
Actual
-$1.91
Surprise
-1.11%
FAQ
What were Amicus Therapeutics, Inc's earnings and revenue for the latest quarter Q4 2025?
For Q4 2025, Amicus Therapeutics, Inc reported EPS of $0.00, missing estimates by -94.35%, and revenue of $185.21M, 0.49% above expectations.
How did the market react to Amicus Therapeutics, Inc's Q4 2025 earnings?
The stock price moved down -0.07%, changed from $14.35 before the earnings release to $14.34 the day after.
When is Amicus Therapeutics, Inc expected to report next?
The next earning report is scheduled for Apr 29, 2026.
What are the forecasts for Amicus Therapeutics, Inc's next earnings report?
Based on 9
analysts, Amicus Therapeutics, Inc is expected to report EPS of $0.03 and revenue of $165.25M for Q1 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement